Pablo Gajate

2.4k total citations
51 papers, 601 citations indexed

About

Pablo Gajate is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Pablo Gajate has authored 51 papers receiving a total of 601 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 19 papers in Surgery and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Pablo Gajate's work include Bladder and Urothelial Cancer Treatments (18 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Neuroendocrine Tumor Research Advances (10 papers). Pablo Gajate is often cited by papers focused on Bladder and Urothelial Cancer Treatments (18 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Neuroendocrine Tumor Research Advances (10 papers). Pablo Gajate collaborates with scholars based in Spain, United States and France. Pablo Gajate's co-authors include Teresa Alonso‐Gordoa, Enrique Grande, Javier Molina‐Cerrillo, Víctor Albarrán, Teresa Alonso, Diana Isabel Rosero, Olga Martínez‐Sáez, Peter Ellinghaus, Cristina Saavedra and Nicolas Penel and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Pablo Gajate

45 papers receiving 597 citations

Peers

Pablo Gajate
Elisabetta Froio Italy
Tahir Latif United States
Virginia Cappagli Italy
Natalyn Hawk United States
Pamela Biondani Italy
T. Geldart United Kingdom
Libing Xiang China
William H. Isacoff United States
Emmanuel Mitry France
Congwei Jia China
Elisabetta Froio Italy
Pablo Gajate
Citations per year, relative to Pablo Gajate Pablo Gajate (= 1×) peers Elisabetta Froio

Countries citing papers authored by Pablo Gajate

Since Specialization
Citations

This map shows the geographic impact of Pablo Gajate's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pablo Gajate with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pablo Gajate more than expected).

Fields of papers citing papers by Pablo Gajate

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pablo Gajate. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pablo Gajate. The network helps show where Pablo Gajate may publish in the future.

Co-authorship network of co-authors of Pablo Gajate

This figure shows the co-authorship network connecting the top 25 collaborators of Pablo Gajate. A scholar is included among the top collaborators of Pablo Gajate based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pablo Gajate. Pablo Gajate is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rodríguez-Moreno, Juan Francisco, Guillermo de Velasco, Carlos Álvarez-Fernández, et al.. (2025). Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial. Clinical Cancer Research. 31(9). 1644–1656.
2.
Guerrero‐Ramos, Félix, Óscar Rodríguez-Faba, Pablo Gajate, et al.. (2025). New insights and emerging approaches in bladder-sparing treatment for muscle-invasive bladder cancer. Actas Urológicas Españolas (English Edition). 49(7). 501758–501758.
3.
Subiela, José Daniel, et al.. (2025). Toxicity Profile of New Therapies in Metastatic Urothelial Carcinoma and Its Impact on Treatment Selection. Cancers. 17(21). 3523–3523.
4.
Sweis, Randy F., Pablo Gajate, Rafael Morales‐Barrera, et al.. (2024). Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer. JAMA Oncology. 10(11). 1565–1565. 6 indexed citations
5.
Lakhani, Nehal J., Omid Hamid, Irene Braña, et al.. (2024). A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results.. Journal of Clinical Oncology. 42(16_suppl). 2650–2650. 2 indexed citations
6.
García‐Fernández, Esther, Pablo Gajate, Antje Dittmann, et al.. (2024). 2005P Prediction of response and identification of mechanisms of resistance to neoadjuvant chemotherapy according to molecular subtypes in muscle-invasive bladder carcinoma. Annals of Oncology. 35. S1158–S1158. 1 indexed citations
7.
Juan-Fita, María José, Urbano Anido Herranz, Carlos Álvarez-Fernández, et al.. (2024). SOGUG-AVELUMAB_RWD: Comprehensive analysis of real-word data to evaluate the effectiveness and safety of avelumab maintenance therapy in patients with stage IV urothelial carcinoma conducted in Spain.. Journal of Clinical Oncology. 42(16_suppl). e16561–e16561. 1 indexed citations
8.
Gajate, Pablo, et al.. (2023). Stereotactic body radiation therapy for kidney cancer. Where do we stand?. International Journal of Urology. 30(5). 437–445. 3 indexed citations
9.
Mar, Nataliya, Yousef Zakharia, Alejandro Falcón, et al.. (2023). Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma. Cancers. 15(11). 2978–2978. 1 indexed citations
10.
López‐Campos, Fernando, Pablo Gajate, Nuria Romero-Laorden, et al.. (2022). Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions. Biomedicines. 10(3). 537–537. 15 indexed citations
11.
12.
Subiela, José Daniel, Daniel A. González‐Padilla, J. Huguet, et al.. (2022). Oncological and Renal Function Outcomes in Patients Who Underwent Simultaneous Radical Cystectomy and Nephroureterectomy for Synchronous or Metachronous Panurothelial Carcinoma. Urology. 172. 157–164. 1 indexed citations
13.
Gajate, Pablo, et al.. (2022). Successful rapid desensitization to atezolizumab in delayed hypersensitivity confirmed with lymphocyte transformation test. The Journal of Allergy and Clinical Immunology In Practice. 10(6). 1649–1651. 5 indexed citations
14.
Grande, Enrique, Cristina Rodríguez‐Antona, Carlos López, et al.. (2021). Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial. The Oncologist. 26(11). 941–949. 16 indexed citations
15.
Doña, Inmaculada, Natalia Blanca‐López, Javier Fernández, et al.. (2021). Clinical Practice Guidelines for Diagnosis and Management of Hypersensitivity Reactions to Quinolones. Journal of Investigational Allergology and Clinical Immunology. 31(4). 292–307. 13 indexed citations
16.
Gajate, Pablo, et al.. (2021). Surgery of pancreatic metastasis from renal cell carcinoma. Cirugía Española (English Edition). 100(1). 50–52. 1 indexed citations
17.
Grande, Enrique, Àlex Teulé, Teresa Alonso‐Gordoa, et al.. (2020). The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). The Oncologist. 25(9). 745–e1265. 24 indexed citations
18.
Pinto, André, Carlos Aguado, Teresa Alonso, et al.. (2019). Collecting Duct Carcinoma of the Kidney: Analysis of Our Experience at the SPANISH ‘Grupo Centro’ of Genitourinary Tumors. 3(3). 177–182. 4 indexed citations
19.
Molina‐Cerrillo, Javier, Teresa Alonso‐Gordoa, Pablo Gajate, & Enrique Grande. (2017). Bruton’s tyrosine kinase (BTK) as a promising target in solid tumors. Cancer Treatment Reviews. 58. 41–50. 100 indexed citations
20.
Gajate, Pablo, Javier Sastre, Inmaculada Bando, et al.. (2012). Influence of KRAS p.G13D Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab. Clinical Colorectal Cancer. 11(4). 291–296. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elisabetta Froio Breakdown of academic impact, for papers by Tahir Latif Breakdown of academic impact, for papers by Virginia Cappagli Breakdown of academic impact, for papers by Natalyn Hawk Breakdown of academic impact, for papers by Pamela Biondani Breakdown of academic impact, for papers by T. Geldart Breakdown of academic impact, for papers by Libing Xiang Breakdown of academic impact, for papers by William H. Isacoff Breakdown of academic impact, for papers by Emmanuel Mitry Breakdown of academic impact, for papers by Congwei Jia
Rankless by CCL
2026